The Incidence of Gallstones After Gastric Cancer Surgery
The Incidence Risks of Gallstones After Radical Surgery in Different Types of Gastric Cancer
1 other identifier
observational
1,019
1 country
2
Brief Summary
Through previous clinical observations and literature, we found that the incidence of gallstones in patients after gastric cancer radical resection was significantly higher than that in the normal population (4%). However, its pathogenesis has not been clarified. We compare the risk of gallbladder stones after four different radical gastric cancer surgical methods, in order to provide prevention and treatment strategies for people with gallstones after gastric cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2020
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2020
CompletedFirst Posted
Study publicly available on registry
January 31, 2020
CompletedStudy Start
First participant enrolled
February 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 16, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 16, 2024
CompletedNovember 19, 2024
November 1, 2024
4.8 years
January 29, 2020
November 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of gallstone patients
Four different gastric cancer patients were followed up for more than 1 year. The number of patients with gallbladder stones revealed by B-ultrasound
3 years
Secondary Outcomes (3)
Number of malignant metastasis
3 years
Number of short-term deaths
3 months
Number of physical regurgitation, nausea, vomiting, diarrhea, constipation
3 years
Study Arms (4)
Arm 1
Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists. Other Name: ESD
Arm 2
Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally.
Arm 3
Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
Arm 4
Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
Interventions
Eligibility Criteria
Gastric cancer patients
You may qualify if:
- Gastric cancer patients
- Age from over 18 to under 75 years
You may not qualify if:
- Gallbladder disease before surgery
- Gallbladder has been remove
- History of previous upper abdominal surgery
- History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
- History of other malignant disease within past five years
- History of previous neoadjuvant chemotherapy or radiotherapy
- History of unstable angina or myocardial infarction within past six months
- History of cerebrovascular accident within past six months
- Requirement of simultaneous surgery for other disease
- Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
- Pregnant women or breastfeeding
- Unwillingness or inability to consent for the study
- Severe mental disorder
- Unstable vital signs Coagulation dysfunction (INR\>1.5)
- Low peripheral blood platelet count (\<50Ă—10 \^9 / L) or using anti- coagulation drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Hepatopancreatobiliary Surgery Institute of Gansu Province
Lanzhou, Gansu, 730000, China
Wuwei turmour hospital
Wuwei, Gansu, 733000, China
Related Publications (2)
Park DJ, Kim KH, Park YS, Ahn SH, Park do J, Kim HH. Risk Factors for Gallstone Formation after Surgery for Gastric Cancer. J Gastric Cancer. 2016 Jun;16(2):98-104. doi: 10.5230/jgc.2016.16.2.98. Epub 2016 Jun 24.
PMID: 27433395BACKGROUNDFurukawa H, Ohashi M, Honda M, Kumagai K, Nunobe S, Sano T, Hiki N. Preservation of the celiac branch of the vagal nerve for pylorus-preserving gastrectomy: is it meaningful? Gastric Cancer. 2018 May;21(3):516-523. doi: 10.1007/s10120-017-0776-8. Epub 2017 Nov 10.
PMID: 29127549BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wenbo Meng, M.D., Ph. D.
Hepatopancreatobiliary Surgery Institute of Gansu Province
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Direct of surgery
Study Record Dates
First Submitted
January 29, 2020
First Posted
January 31, 2020
Study Start
February 14, 2020
Primary Completion
November 16, 2024
Study Completion
November 16, 2024
Last Updated
November 19, 2024
Record last verified: 2024-11